Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism

  1. de Andrés-Nogales, F.
  2. Oyagüez, I.
  3. Álvarez-Sala, L.A.
  4. García-Bragado, F.
  5. Navarro, A.
  6. González, P.
  7. Elías, I.
  8. Soto, J.
Revue:
Pharmacoeconomics - Spanish Research Articles

ISSN: 1989-5453,  1695-405X

Année de publication: 2017

Volumen: 14

Número: 1

Pages: 7-18

Type: Article

DOI: 10.1007/S40277-016-0064-8 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus